The 2024 ESMO Annual Congress was host to the session Updates in the management of advanced renal cell carcinoma. Dr. Teresa Alonso Gordoa discussed systemic treatment options for the management of ...

Saikali S, Khosravi P, Gamal A, et al. MP07-02 Detection of Prostate Cancer Extracapsular Extension with MRI Using Deep Learning Methods. J Urol. 2024 May;211 (5S):e105.

The encore results from the Phase 3 BOND-003 Cohort C study demonstrate that intravesical cretostimogene grenadenorepvec provides a high complete response rate (74.5%) in patients with ...

As we celebrate Women's History Month, we recognize the many incredible women who have contributed to educating the global urology and oncology communities through UroToday-GU Oncology Today®. We ...

Arjun Pon Avudaiappan presented a study comparing radical prostatectomy versus dose-escalated radiation with ADT in node-positive prostate cancer, using data from the National Cancer Database. The ...

Prostate cancer represents a significant oncological challenge, with its natural history predominantly driven by androgen receptor (AR) signaling. The pivotal role of this pathway underscores the ...

One of the major limitations for clinical applications of infrared spectroscopic imaging modalities is the acquisition time required to obtain reasonable images of tissues with high spatial resolution ...

Lysine-specific demethylase 1 (LSD1) is a histone demethylase and regulator of differentiation, including in cancer. A neuronal-specific isoform of LSD1-LSD1+8a-has been shown to play a key role in ...

To clarify the long-term prognoses of elderly upper tract urothelial carcinoma (UTUC) patients after surgery. We used a hospital-based cancer registry data in Japan to extract patients with pT1-3N0M0 ...

To compare the impact of on-table monitoring vs standard-of-care multiparametric MRI (mpMRI) for the utilisation of gadolinium contrast use in prostate MRI. This retrospective observation study of ...

Rationale: [177Lu]Lutetium prostate-specific membrane antigen radioligand therapy ([177Lu]Lu-PSMA) is EMA-approved for certain indications in metastatic castration resistant prostate cancer (mCRPC).